Swift S M, Rose S, London N J, James R F
Department of Surgery, University of Leicester, UK.
Transpl Immunol. 1996 Jun;4(2):169-76. doi: 10.1016/s0966-3274(96)80012-8.
Although human islet allotransplantation has been shown to be effective in restoring normoglycaemia to diabetic recipients, the long-term success rate is relatively low. The poor results of human islet transplantation are surprising given the relative ease of establishing functioning islet allografts in rodent models with minimal immunosuppression and have been attributed to a number of factors of which rejection may play a major part. The impracticality of studying the immunogenicity of human islets in vivo has led us to develop a model specifically to study the allogeneic immune response to the major components of isolated human islet preparations. To try and overcome the variability associated with this methodology, this study was designed to develop and optimize the mixed lymphocyte coculture as an in vitro model for the initial alloresponse to both freshly isolated intact human islets (MLIC) and acinar tissue pieces (MLAC). For this, titration of the islets and acinar tissue, as well as kinetic studies of the response, were used to select optimum conditions for the MLIC which were shown to be ten islets and ten acinar tissue pieces with a coculture duration of 7-9 days. The optimized studies included the use of non-tissue culture microwells to deter fibroblast growth, RPMI + 10% human AB serum to reduce the background lymphocyte response and a low concentration of dithizone to stain the islets prior to handpicking. Freshly isolated human islets were found to stimulate allogeneic lymphocytic proliferation; however, differences in the relative response to islets and acinar tissue led us to test the effect of soluble products from the acinar cells on lymphocyte proliferation in the mixed lymphocyte reaction. An inhibitory effect of the soluble products of acinar cells on the allogeneic lymphocyte proliferative response was found to contribute to the reduced response of the MLAC compared to the MLIC. Human islets were shown to stimulate an allogeneic immune response in vitro, and this MLIC model provides a method for assessing the specific immunogenicity of human isolated islet preparations and associated acinar tissue in transplantation.
尽管人类胰岛同种异体移植已被证明能有效使糖尿病受者恢复正常血糖,但长期成功率相对较低。鉴于在啮齿动物模型中以最小的免疫抑制建立起功能正常的胰岛同种异体移植相对容易,人类胰岛移植的不佳结果令人惊讶,这归因于多种因素,其中排斥反应可能起主要作用。在体内研究人类胰岛免疫原性不切实际,这促使我们开发一种专门模型来研究对分离的人类胰岛制剂主要成分的同种异体免疫反应。为尝试克服与该方法相关的变异性,本研究旨在开发并优化混合淋巴细胞共培养,作为对新鲜分离的完整人类胰岛(MLIC)和腺泡组织块(MLAC)初始同种异体反应的体外模型。为此,通过胰岛和腺泡组织的滴定以及反应动力学研究,为MLIC选择最佳条件,结果显示为十个胰岛和十个腺泡组织块,共培养持续时间为7 - 9天。优化研究包括使用非组织培养微孔以抑制成纤维细胞生长、RPMI + 10%人AB血清以降低背景淋巴细胞反应,以及在手工挑选前用低浓度双硫腙对胰岛进行染色。发现新鲜分离的人类胰岛能刺激同种异体淋巴细胞增殖;然而,对胰岛和腺泡组织相对反应的差异促使我们测试腺泡细胞可溶性产物对混合淋巴细胞反应中淋巴细胞增殖的影响。发现腺泡细胞可溶性产物对同种异体淋巴细胞增殖反应有抑制作用,这导致MLAC与MLIC相比反应降低。人类胰岛在体外显示能刺激同种异体免疫反应,并且这种MLIC模型提供了一种评估移植中人类分离胰岛制剂及相关腺泡组织特异性免疫原性的方法。